NCT05649670

Brief Summary

ASPHALT is an academic-driven open-label randomized controlled trial of Mobile Stroke Unit (MSU) deployment versus standard care in France, with blinded assessment of efficacy endpoints. 450 patients with confirmed acute ischemic stroke will be recruited over a 3-year period, with 3-month follow-up.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P75+ for not_applicable

Timeline
13mo left

Started Oct 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

11 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Oct 2023Jun 2027

First Submitted

Initial submission to the registry

December 2, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 14, 2022

Completed
10 months until next milestone

Study Start

First participant enrolled

October 16, 2023

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 16, 2026

Expected
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 16, 2027

Last Updated

February 1, 2024

Status Verified

October 1, 2023

Enrollment Period

3 years

First QC Date

December 2, 2022

Last Update Submit

January 31, 2024

Conditions

Keywords

Mobile Stroke UnitMSUIntravenous thrombolysisEmergency Medical ServiceMechanical thrombectomyCost-utilityCost-effectiveness

Outcome Measures

Primary Outcomes (2)

  • Incremental Cost-Utility Ratio (ICUR)

    ICUR in the lifetime horizon, based on extrapolated results of the Modified Rankin Scale (mRS) at 3 months and incremental costs prospectively collected during the first 3 months

    3 months

  • Key secondary outcome: Modified Rankin Scale (mRS) at 3 months

    Modified Rankin scale, assessed in a blinded fashion (range, 0 to 6, with 0 indicating no disability, 3 indicating moderate disability, and 6 indicating death)

    90 +/- 14 days

Secondary Outcomes (12)

  • ICUR at 3 months

    90 +/- 14 days

  • ICUR at 5 years

    5 years

  • Time from symptom onset to intravenous thrombolysis (IVT)

    up to 4.5 hours from symptom onset

  • Time from symptom onset to mechanical thrombectomy (MT)

    up to 24 hours from symptom onset

  • Time from alarm to IVT

    up to 4.5 hours from symptom onset

  • +7 more secondary outcomes

Study Arms (2)

Intervention (MSU)

EXPERIMENTAL

Deployment of MSU + conventional ambulance

Other: Mobile Stroke Unit deployment

Control (usual care)

NO INTERVENTION

Deployment of conventional ambulance

Interventions

Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).

Also known as: Mobile Stroke Unit management
Intervention (MSU)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Emergency call to one of the two following emergency medical service (EMS) dispatch centers : SAMU (Service d'Aide Médicale Urgente) or BSPP (Brigade des Sapeurs Pompiers de Paris), between 08:00 and 18:00, 5 days a week (Monday to Friday).
  • Suspected acute stroke according to a dispatcher stroke identification algorithm, adapted from the ROSIER scale
  • Symptom onset-to-randomization time ≤ 6h
  • Patient located within the predefined catchment area of the MSU
  • MSU available at the time of the EMS call
  • Informed consent (as approved by the ethics committee, informed consent will be obtained after randomization: at the arrival of the MSU (intervention group), or at hospital arrival (control group))

You may not qualify if:

  • Patient confined to be more than 50% of waking hours
  • Unknown or uncertain onset time (e.g. wake-up stroke)
  • Medical history of epilepsy
  • Recent epileptic seizure (\<12 hrs)
  • Suspicion of pregnancy
  • Parturient or breastfeeding woman
  • Patient already participating in another interventional study, which could influence the mRS at 3 months.
  • Patient under guardianship or curatorship
  • Patient not affiliated to French Social Security

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

AP-HP - hôpital Raymond Poincaré

Garches, 92380, France

RECRUITING

AP-HP - hôpital Bicêtre

Le Kremlin-Bicêtre, 94275, France

RECRUITING

AP-HP - hôpital Lariboisière

Paris, 75010, France

RECRUITING

AP-HP - hôpital de la Pitié-Salpêtrière

Paris, 75013, France

RECRUITING

GHU Paris psychiatrie & neurosciences

Paris, 75014, France

RECRUITING

SAMU 75 de Paris

Paris, 75015, France

RECRUITING

BSPP, Brigade des Sapeurs-Pompiers de Paris

Paris, 75017, France

RECRUITING

AP-HP - hôpital Bichat - Claude-Bernard

Paris, 75018, France

RECRUITING

Fondation Ophtalmologique Rothschild

Paris, 75019, France

RECRUITING

Hôpital Saint Joseph

Paris, 75674, France

NOT YET RECRUITING

Hôpital Foch

Suresnes, 92151, France

RECRUITING

Related Publications (1)

  • Turc G, Hadziahmetovic M, Walter S, Churilov L, Larsen K, Grotta JC, Yamal JM, Bowry R, Katsanos AH, Zhao H, Donnan G, Davis SM, Hussain MS, Uchino K, Helwig SA, Johns H, Weber JE, Nolte CH, Kunz A, Steiner T, Sacco S, Ebinger M, Tsivgoulis G, Fassbender K, Audebert HJ. Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis. JAMA Neurol. 2022 Mar 1;79(3):281-290. doi: 10.1001/jamaneurol.2021.5321.

    PMID: 35129584BACKGROUND

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Guillaume TURC, MD, PhD

    GHU Paris Psychiatrie et Neurosciences

    PRINCIPAL INVESTIGATOR
  • Benoît VIVIEN, MD, PhD

    APHP - Centre Hospitalier Universitaire Necker

    STUDY DIRECTOR

Central Study Contacts

Khaoussou SYLLA, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Blinded assessment of 3-month mRS (via telephone interview)
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized controlled trial, PROBE design
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 2, 2022

First Posted

December 14, 2022

Study Start

October 16, 2023

Primary Completion (Estimated)

October 16, 2026

Study Completion (Estimated)

June 16, 2027

Last Updated

February 1, 2024

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will share

Individual participant data (IPD) could be available to other researcher aiming to conduct an IPD-meta analysis of studies of MSU vs. usual care (please see access criteria below).

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Two years after the last publication
Access Criteria
Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. Data sharing must respect the agreements made with funders. Teams wishing to obtain IPD must meet the sponsor and PI team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and time frame. Technical feasibility and financial support will be discussed before mandatory contractual agreement. Processing of shared data must comply with European General Data Protection Regulation (GDPR).

Locations